| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.41 | 2e-13 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.39 | 3e-12 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.23 | 0.0001 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.16 | 0.005 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.15 | 0.01 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.14 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.11 | 0.07 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.077 | 0.2 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.076 | 0.2 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.072 | 0.2 |